Fenbufen
Based on 1 publication(s) in Google Scholar
Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.50%
- CAS No.: 36330-85-5
- Formula: C16H14O3
- Molecular Weight:254.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Protease Inhibitor Library
HY-L147
-
Immunopotentiator Compound Library
HY-L172
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Fenbufen
MoreAll Caspase Isoforms
More
Biological Activity
|
COX-1 3.9 μM (IC50) |
COX-2 8.1 μM (IC50) |
Caspase-1 4.4 μM (IC50) |
Caspase-3 1.2 μM (IC50) |
Caspase-4 0.57 μM (IC50) |
Caspase-5 0.87 μM (IC50) |
Caspase-9 0.76 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 3
|
Cytotoxicity against human A549 cells after 2 days by MTT assay
Cytotoxicity against human A549 cells after 2 days by MTT assay
|
[PMID: 21315586] |
| MCF7 | IC50 |
>50 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells after 2 days by MTT assay
Cytotoxicity against human MCF7 cells after 2 days by MTT assay
|
[PMID: 21315586] |
Fenbufenmay (1200 mg/kg; p.o.; diet; for 10 days) blocks the hypertrophy of the heart but not that of the skeletal muscles[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male hooded Lister rats[6]
-
Dosage:1200 mg/kg
-
Administration:Oral administration, diet, for 10 days
-
Result:Significantly reduced Clenbuterol (2mg/kg)-induced hypertrophy of the heart.
Chemical Information
-
CAS No. 36330-85-5
-
Appearance Solid
-
Molecular Weight 254.28
-
Formula C16H14O3
-
Color White to off-white
-
SMILES
O=C(O)CCC(C1=CC=C(C2=CC=CC=C2)C=C1)=O
-
Synonyms
CL-82204
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
Solvent & Solubility
DMSO : 50 mg/mL (196.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (9.83 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. A E Sloboda, et al. The pharmacological properties of fenbufen. A review. Arzneimittelforschung. 1980;30(4A):716-21. [Content Brief]
[2]. R G Child, et al. Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relationships of analogs, J Pharm Sci. 1977 Apr;66(4):466-76. [Content Brief]
[3]. A E Sloboda, et al. The pharmacology of fenbufen, 3-(4-biphenylylcarbonyl)propionic acid, and 4-biphenylacetic acid, interesting antiinflammatory-analgesic agents. Inflammation. 1976 Dec;1(4):415-38. [Content Brief]
[4]. Asif Husain, et al. Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem . 2009 Sep;44(9):3798-804. [Content Brief]
[5]. Christina E Smith, et al. Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors. Cell Chem Biol. 2017 Mar 16;24(3):281-292. [Content Brief]
[6]. R M Palmer, et al. Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. Br J Pharmacol. 1990 Dec;101(4):835-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9327 mL | 19.6634 mL | 39.3267 mL | 98.3168 mL |
| 5 mM | 0.7865 mL | 3.9327 mL | 7.8653 mL | 19.6634 mL | |
| 10 mM | 0.3933 mL | 1.9663 mL | 3.9327 mL | 9.8317 mL | |
| 15 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL | 6.5545 mL | |
| 20 mM | 0.1966 mL | 0.9832 mL | 1.9663 mL | 4.9158 mL | |
| 25 mM | 0.1573 mL | 0.7865 mL | 1.5731 mL | 3.9327 mL | |
| 30 mM | 0.1311 mL | 0.6554 mL | 1.3109 mL | 3.2772 mL | |
| 40 mM | 0.0983 mL | 0.4916 mL | 0.9832 mL | 2.4579 mL | |
| 50 mM | 0.0787 mL | 0.3933 mL | 0.7865 mL | 1.9663 mL | |
| 60 mM | 0.0655 mL | 0.3277 mL | 0.6554 mL | 1.6386 mL | |
| 80 mM | 0.0492 mL | 0.2458 mL | 0.4916 mL | 1.2290 mL | |
| 100 mM | 0.0393 mL | 0.1966 mL | 0.3933 mL | 0.9832 mL |
Powered by Bioz